Surmodics to Webcast Second Quarter Fiscal 2018 Earnings Conference Call on May 2
Webcast is Live at 7:30 a.m. (CT)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Apr. 24, 2018--
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in
vitro diagnostic technologies to the healthcare industry, today
announced that it will host a live webcast of its second quarter fiscal
2018 conference call on Wednesday, May 2, at 7:30 a.m. CT (8:30 a.m.
ET). The Company will issue an earnings news release earlier that
Gary Maharaj, president and chief executive officer, and Andy LaFrence,
vice president of finance and information systems and chief financial
officer, will recap the second quarter fiscal 2018 financial results and
accomplishments. To access the webcast, go to the investor relations
portion of the Company’s website at www.surmodics.com
the day of the conference call and click on the webcast icon.
An audio replay will be available beginning at 10:30 a.m. CT on
Wednesday, May 2, until 10:30 a.m. CT on Wednesday, May 9, and can be
accessed by dialing 888-203-1112 and entering conference call ID
passcode 4717236. In addition, the conference call audio and transcript
will be archived on the Company’s website following the call.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for
intravascular medical devices and a leading provider of chemical
components for in vitro diagnostic (IVD) immunoassay tests
and microarrays. Surmodics is pursuing highly differentiated
whole-product solutions that are designed to address unmet clinical
needs for its medical device customers and engineered to the most
demanding requirements. This key growth strategy leverages the
combination of the Company’s expertise in proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities. The Company mission remains to improve the
detection and treatment of disease. Surmodics is headquartered in Eden
Prairie, Minnesota. For more information, visit www.surmodics.com. The
content of Surmodics’ website is not part of this press release or part
of any filings that the company makes with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180424005272/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000